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Abstract 
Background: The methyl-xanthine drug theophylline has been used for the treatment of asthma and 
chronic obstructive pulmonary disease (COPD) for several decades. Phosphodiesterase inhibition 
leading to smooth muscle relaxation is its main mode of action as a broncho-dilating agent, requiring 
blood theophylline concentrations close to the toxic range and a consequent problem with side 
effects. It also has anti-inflammatory effects that occur at relatively low concentrations. 
Objective: To explore supporting evidence for how other properties of theophylline could be of 
considerable clinical utility, particularly in reducing weakness and overt sarcopenia, based on its anti-
inflammatory, steroid-sparing and immune-modulating properties.  
Methods: PUBMED and MEDLINE were scanned using the search terms: theophylline, anti-
inflammatory, cytokine, inflammation, ageing, sarcopenia, frailty, chronic obstructive airways 
disease, pulmonary rehabilitation. High quality articles were selected, read in depth and discussed 
by the authors, then used as the basis for a proposition on the potential anti-inflammatory and anti-
sarcopenic use of theophylline. 
Findings: The anti-inflammatory properties of theophylline are mainly mediated by histone 
deacetylase induction in immune competent cells with a resulting shift toward the expression of a 
less inflamed phenotype, including a reduction of the release of pro-inflammatory cytokines and 
associated increase in anti-inflammatory cytokines. These effects occur at blood theophylline 
concentrations well below the range for direct broncho-dilatation.  
Conclusion: There are potential therapeutic benefits of theophylline that are systemic and not 
confined to airways inflammation in COPD. There is scope for a beneficial effect in other chronic 
inflammatory states and post-acute inflammation with slow resolution. There is compelling evidence 
that theophylline could be used for anti-inflammatory adjunctive treatment to improve independent 
function, muscle strength and other outcomes in individuals recovering from acute inflammatory 
episodes, including but not limited to exacerbations of COPD, and as a pharmaceutical intervention 
in support of pulmonary rehabilitation. 
Key words: theophylline, chronic obstructive pulmonary disease, systemic inflammation, immune 
modulation, sarcopenia, illness behaviour, pulmonary rehabilitation 
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Introduction 
Theophylline was first identified in the late 19th century as a drug occurring naturally in tea and 
cocoa. It was synthesized a few years later and came into clinical use, initially as a diuretic, in 1902. 
Its other pharmacological properties gradually became apparent and it was used to relieve the 
symptoms of asthma from around 1922 [1]. The mechanisms of action of theophylline, and other  
methyl-xanthine drugs such as caffeine, theobromine and pentoxifylline, have progressively come to 
light. The rapid-action bronchodilator effect of theophylline is mainly due to phosphodiesterase 
inhibition and subsequent smooth muscle relaxation.  Later, the antagonist effect of theophylline on 
adenosine receptors was demonstrated and is the principal reason for the positive inotropic and 
chronotropic cardiac effects observed, and the most likely explanation for the central nervous 
system stimulation and respiratory stimulant properties of that class of drugs [2]. Adenosine 
receptor antagonism probably also contributes to the bronchodilator effect and is also the 
mechanism whereby theophylline reduces nitrous oxide production by endothelial cells [2,3].  
Although theophylline, and its derivative for intravenous use, aminophylline, still have a role in the 
management of asthma and chronic obstructive pulmonary disease (COPD) [4], their use has been 
limited in recent decades by the emergence of more effective and less toxic beta-agonist and anti-
muscarinic bronchodilator drugs. The plasma concentrations of theophylline required for useful 
bronchodilatation (10-15 mg/L) are close to the overtly toxic range (> 20 mg/L) at which a number of 
unpleasant and potentially dangerous side-effects occur, such as nausea, vomiting, tremor, cardiac 
arrhythmias, agitation, insomnia and seizures. Further, the elimination half-life of theophylline varies 
greatly with age, renal function, liver function, thyroid function, smoking, heart failure and pyrexia. 
The toxic effects are accentuated by a number of commonly used drugs such as erythromycin and 
ciprofloxacin, and rapid absorption leading to toxic blood levels can occur if an oral dose is taken 
with a fatty meal [5]. Consequently, interest in theophylline as a therapeutic agent in the context of 
obstructive airways disease has waned and is currently confined to certain adjunctive roles such as 
those defined in the British Thoracic Society guideline for COPD and asthma [4]. However, a growing 
understanding of the actions of theophylline as an immune-modulatory agent, particularly in the 
relatively non-toxic dose range (5-10 mg/L), opens a potential new role for the drug in ameliorating 
the deleterious effects of sustained systemic inflammation [2, 6-8] particularly on muscle function, 
cognition and mood after exacerbations of COPD and other pro-inflammatory events. That topic is 
the subject of this paper. 
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Search methods 
The electronic medical databases PUBMED and MEDLINE were scanned using the search terms: 
theophylline, anti-inflammatory, cytokine, inflammation, ageing, sarcopenia, frailty, chronic 
obstructive airways disease, pulmonary rehabilitation from 1990-2018. More than 500 articles were 
identified and 95 papers judged to be of good quality and relevant to the topic were selected to be 
read in depth and discussed by the authors. No other form of selection was applied. Some other 
sources were taken into consideration, mainly for background information. We have cited only the 
most important sources. The proposition presented in this paper emerged from discussions between 
the authors, supported by the discovered literature.   
 
Background – innate immune function and dysfunction 
Innate immunity 
To set the context for the suggestions made later in this paper it is necessary to describe some key 
aspects of the innate immune system, the cells and cytokines of which are the initial line of defence 
against infection and other forms of tissue damage[9]. The chemistry and cell biology of innate 
immunity is complex and incompletely understood and is outside the scope of this paper. Empirical 
findings have varied but there is a sufficient amount of verified research to provide a useful 
understanding of a number of key processes. Taking pneumococcal infection as an example, in 
individuals with or without adaptive antibody immunity, pneumococcal antigens are initially 
presented to tissue macrophages and circulating monocytes both directly and as complexes bound 
to C-reactive protein (CRP), serum amyloid A (SAA) and toll-like proteins. In response, monocytes of 
pro-inflammatory phenotype release inflammatory cytokines of the interleukin-1 (IL-1) family, 
principally IL-1β, interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNFα), probably within 1-3 
hours as shown by in vitro studies [10,11]. There is some evidence that this process is delayed in 
older patients, based on studies in a clinical setting [12], but the clinical significance of that finding is 
not clear. By processes for which there is only a partial understanding those cytokines, other less 
extensively studied cytokines, and other bio-chemicals involved in innate immunity such as 
interferons and complement, stimulate a number of responses by a wide range of cell types that 
contribute to an effective elimination of the infection. The range of these pro-inflammatory effects 
also includes increased production of CRP and SAA by hepatocytes, increased endothelial 
permeability, reduced myoprotein synthesis and increased IL-6 release by various cells including 
monocytes, myocytes and adipocytes, reduced albumin synthesis, switching of neutrophils to a pro-
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inflammatory phenotype that results in further release of pro-inflammatory cytokines including 
TNFα, down-regulation of autonomic cardiovascular reflexes, and context-variable effects on 
synthetic functions by other tissues and metabolic pathways including glucocorticoid and 
catecholamine production [13,14]. Lethargy and an urge to rest, sometimes referred to as sickness 
behaviour, are probably at least partly due to cytokine-mediated alterations in central nervous 
system function. This particular adverse consequence is of considerable clinical importance. Equally 
important, there is circumstantial evidence that pro-inflammatory cytokines directly predispose to 
delirium [15,16], though the mechanism is not clear and other factors might be involved. There is a 
complex sequential effect on macrophages leading initially to further production of IL-1β, TNFα and 
the anti-inflammatory cytokines interleukin-4 (IL-4) and IL-1 receptor antagonist (IL-1ra). Antigen-
stimulated monocytes are also self-stimulated to release TNFα and other cytokines by an autocrine 
mechanism and, through an influence on T-helper cell function, lead to rapid production and release 
of interferon gamma (IFγ), which in turn contributes to the response to infection by a range of 
interactions with cells of the innate and adaptive immune systems. In the early and mature phases 
of this pro-inflammatory response the primary purposes of eliminating infection, minimising damage 
and the survival of the individual are being served. Once infection has been eliminated counter-
regulatory mechanisms switch the chemokine and cellular milieu of the innate immune system to an 
anti-inflammatory phase characterized by a rapid fall in IL-1β, TNFα, other pro-inflammatory 
cytokines and CRP, a transient rise in blood levels of anti-inflammatory cytokines such as IL-4, 
interleukin-10 (IL-10) and IL-1ra, and a return of immune cell phenotypes to mainly anti-
inflammatory and surveillance mode [16].  
 
Chronic inflammation, sarcopenia and ageing 
To provide background from another perspective it is important to consider the inflammatory state 
associated with chronic disease and old age as this closely approximates to the condition of many 
patients with COPD. Baseline biochemical markers of inflammation, such as IL-1β, TNFα and CRP are 
often chronically raised 2- to 4- fold in the peripheral blood of older people, particularly those above 
the age of 80 years and, or, with multiple co-morbidities, compared with younger adults [17,18]. The 
reason for this is not entirely clear, but in some it can be explained by the presence of a clinically 
obvious chronic inflammatory pathology, with COPD as one of the commonest examples, and with a 
range of other disorders such as rheumatoid arthritis [19]. Similar levels of baseline TNFα and CRP 
are often found in people with other pathological states that are known to have a pro-inflammatory 
effect, such as central obesity, atherosclerosis or type 2 diabetes [20,21]. Several other conditions, 
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associated with the depleted physiological state that characterizes frailty, have been shown to be 
accompanied by chronically raised pro-inflammatory markers, though the cause-and-effect 
relationship is less clear. These include Alzheimer’s disease, chronic kidney disease, osteoarthritis 
and physical inactivity [22-24]. Some studies have described elevated baseline CRP and pro-
inflammatory cytokines in elderly people with no apparent underlying chronic disease [19], thus 
supporting the contention that old age is in itself a pro-inflammatory condition. Patients with COPD 
have chronic inflammation in their airways and systemically. Further, an episode of exacerbation is 
characterized by a rise in blood inflammatory markers during and after the episode. This includes 
CRP and the pro-inflammatory cytokines mentioned above, as well as several other markers 
including IL-8 (strongly associated with lung inflammation), fibrinogen, leukotrienes, leptin, 
endothelin-1, and myeloperoxidase [25]. In its chronic state, persisting low-amplitude inflammation 
is linked to a number of important adverse outcomes, including increased all-cause mortality, 
reduced muscle strength, impaired ability to carry out essential activities of daily living and lower 
self-reported health status [26]. Further, it appears that chronic disease progression is at least partly 
a consequence of chronic inflammation and not simply a manifestation of it; there appears to be a 
complex interaction between cause and effect that is self-sustaining and deleterious [27]. A non-
pulmonary example of this is the endothelial inflammation that occurs in atheromatous vascular 
disease, which can be envisaged as a destructive endo-vasculitis both resulting from and stimulating 
an enhanced systemic pro-inflammatory baseline state associated with enhanced endothelial nitrous 
oxide release [28]. This chronic slightly inflamed state, with the associated and probably consequent 
increase in vulnerability to an overtly frail clinical condition is also of clinical and functional 
importance in patients with COPD, particularly those who are likely to develop muscle weakness or 
are already overtly sarcopenic. Such individuals are thereby at risk of impaired locomotor function, 
worsening exercise intolerance and reduced respiratory muscle strength. This concept leads in the 
following paragraph to a consideration of the deterioration that occurs when an acute infection, or 
other source of inflammation, is superimposed.  
 
The deleterious effect of an extended acute pro-inflammatory state  
At this point we will consider the possible mechanisms whereby TNFα, IL-1β, IL-6 and other 
inflammatory bio-chemicals contribute to adverse clinical phenomena in COPD and similar 
conditions. An important example from the clinical perspective is inflammation-associated neuronal 
dysfunction. There is evidence that pro-inflammatory over-activity, and inadequate or incomplete 
anti-inflammatory resolution contribute to delirium, low mood and sickness behaviour, all of which 
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are of considerable importance in the day-to-day clinical setting [29]. Autonomic dysfunction is 
another probable consequence, though interpretation is to some extent confounded by the 
immuno-regulatory role of autonomic neuroendocrine pathways. Receptors for several cytokines are 
present on neurons and glial cells, including TNFα, IL-1β, IL-6 and IL-1ra. Moreover, transport 
systems have been demonstrated that enable a number of cytokines to enter the cerebro-spinal 
fluid and brain interstitial fluid, including IL-1β, TNFα, IL-6 and IL-1ra [30-33]. In animal experiments 
it has been shown that measurable changes of behaviour, such as anorexia, hiding and sleepiness, 
are induced by artificial exposure to IL-1β and TNFα [34], which probably act via hypothalamic 
neurons. The role of cytokines in neuronal function is complex and appears to be both deleterious 
and protective depending on the metabolic and patho-physiological context [34-36]. Recent in vitro 
evidence suggests that the influence of cytokines on brain function is to a considerable extent 
mediated by receptors on various cell types in the blood-brain barrier, leading to changes in 
permeability and the secondary production of pro-inflammatory cytokines on the brain side of the 
barrier by glial cells [35]. In any case, the real-time association of elevated concentrations of IL-1β, 
IL-6 and TNFα in peripheral blood with neuronal dysfunction during and after infection, particularly 
physiologically depleted and elderly individuals, is strongly suggestive that those cytokines are either 
directly or indirectly involved [37].  
Though some of the adverse effects of IL-1β and TNFα are due to direct receptor-mediated changes 
in cell metabolism, there is evidence of widespread influences of a sustained pro-inflammatory state 
on other metabolic pathways and cell functions that are less clearly direct. These include changes in 
insulin sensitivity, increased catecholamine and glucocorticoid secretion, increased production of 
reactive oxygen species and nitrous oxide in endothelium, augmented production of prostaglandins 
and stimulation of interferon-gamma (IFγ) release. Important indirect mechanisms include 
complement-mediated micro-coagulation as a consequence of a pro-inflammatory state [38].  The 
biological consequences of these changes are incompletely understood but some of the better 
described phenomena are of considerable importance in clinical practice, particularly the central and 
peripheral neuronal effects described above, reduced muscle protein synthesis, impaired myocyte 
function and increased capillary permeability, all of which can contribute to the syndrome of frailty 
and impaired function.   
 
 
The anti-inflammatory properties of theophylline 
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More recently, the anti-inflammatory properties of theophylline and related drugs has been 
recognized. It was observed, in the context of COPD, that patients taking theophylline had more 
favourable outcomes in certain domains after acute exacerbations, particularly walking performance 
and a subjective feeling of being less exhausted [39]. Moreover, these effects appeared to be 
preserved at plasma theophylline concentrations (< 10 mg/L) below the range required for useful 
bronchodilatation (10-15 mg/L) and therefore well below the toxic range (> 20 mg/L) [39,40]. 
Further, it was found that theophylline exhibited an anti-inflammatory effect locally on the inflamed 
airways of COPD patients, and systemically in clinical studies and in isolated tissue in the laboratory 
[41]. Other methyl-xanthine drugs have been shown to have similar properties, though most of the 
evidence pertains to theophylline. The mechanisms of action have not been completely resolved at 
the molecular level but it has been shown that theophylline reduces the production by monocytes 
and other immune cells of the pro-inflammatory cytokines tumour necrosis factor alpha (TNFα) and 
interleukin-1 beta (IL-1β) and increases the release of the anti-inflammatory cytokines IL-4 and 
interleukin-10 (IL-10) [42-44]. This has been shown to be mediated epigenetically through the 
induction of histone deactylase-dependent gene switching, leading to the expression of a less pro-
inflammatory and more anti-inflammatory cell phenotype [43] (figure 1). This mechanism, and other 
associated gene switches that up- and down-regulate a range of cytokines, have been found to be 
dose-dependent but do not appear to require the high doses needed for bronchodilatation [42]. 
Interestingly, it has been observed in patients with COPD that the addition of theophylline to a 
standard drug regimen resulted in lower baseline C-reactive protein (CRP) levels and better 
functional scores compared to matched controls [45]. In that context, CRP can be seen as a broad 
indicator of the inflammatory state of the patient as its synthesis and release from hepatocytes are 
directly influenced by IL-1 and trough IL-6. It can be contended that the reduction of pro-
inflammatory cytokines by theophylline is a feasible explanation for that observation. Theophylline 
antagonises endothelial adenosine receptors and the resulting reduction in nitrous oxide synthesis 
limits the rise in capillary permeability that can result from systemic inflammation [3]. It has also 
been shown to have a steroid sparing effect in acute exacerbations of COPD and asthma [2,46,47], 
which is thought to be largely due to its anti-inflammatory properties, and probably to some extent 
to adjunctive bronchodilator action. Theophylline also reduces interleukin-6 (IL-6) levels in the 
peripheral blood of people with a number of chronic inflammatory disorders, including COPD. 
However, the role of IL-6 in inflammation is complex and varies with the physiological context. It is 
not simply a pro-inflammatory cytokine and is released as a myokine from skeletal muscle during 
exercise, as well as from immune cells in response to infection and other inflammatory stimuli. The 
rapid transient rise in IL-6 during exercise appears to have an overall anti-inflammatory effect, 
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possibly through IL-6 mediated release of IL-10, and also through increasing insulin receptor 
sensitivity and other anti-sarcopenic effects on skeletal myocytes. By comparison, the high resting 
trough IL-6 levels found in peripheral blood in chronic and sub-acute inflammatory states and 
trauma are associated with a higher risk of delirium and an enhanced risk of sarcopenia and lower 
functional performance [48-55]. There is no reliable evidence of the effect of theophylline on post-
exercise or trough IL-6 levels in peripheral blood in subjects with COPD, other inflammatory states or 
frailty indicators. 
 
Implications for clinical practice 
In the paragraphs above we have presented the background science pertaining to the clinical 
consequences of prolonged or chronic low level systemic inflammation. In patients in a pre-frail or 
overtly frail condition, such as many with COPD, and in old age, it has been consistently observed 
that inflammation is causally linked with a number of common adverse effects. Those with the 
greatest impact on individuals and on service provision are muscle weakness and sarcopenia 
(limiting mobility and independent function, and increasing the risk of falls), sickness behaviour and 
lethargy (lowering mood and predisposing to social and functional withdrawal), reduced appetite 
(compromising nutrition and hydration) and delirium (greatly increasing dependency, direct care 
needs and the risk of injury). At present, there have been no properly structured clinical trials of the 
role of immune modulating drugs in the management of systemic inflammation. However, we 
contend that based on the existing clinical and laboratory observations discussed in this paper, 
theophylline is a potential candidate for targeted trials, with particular attention to the adverse 
outcomes mentioned in this paragraph. The following paragraph enlarges on that concept.  
 
Theophylline as an immune modulating drug in COPD and similar conditions 
Based on the evidence presented above we suggest that theophylline at target plasma levels 
between 5 and 10 mg/L could be deployed to down-regulate the pro-inflammatory state in COPD, 
particularly in the aftermath of acute exacerbations. This could lead to measurable and clinically 
significant improvements in function, particularly muscle strength, mobility and mood. The likely 
mediator of such benefits would be reduced production of TNFα and other pro-inflammatory 
components of the innate immune system, and concomitant, or consequential, up-regulation of the 
production of IL-10 and other anti-inflammatory bio-chemicals and immune cell phenotypes. We 
also contend that such an alteration in the overall balance of pro-inflammatory and anti-
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inflammatory cytokines will lead to earlier and more complete resolution of the post-infective or 
post-exacerbation systemic inflamed state frequently observed in patients with COPD, and other 
inflamed states. Any such benefit might be especially helpful in elderly pre-frail patients with 
depleted physiological reserves. 
This proposition is of course based on certain reasonable suppositions. Firstly, that the adverse 
clinical outcomes described above are at least partly caused by persisting systemic inflammation and 
that by applying an intervention to reduce the duration and amplitude of that inflammation the 
outcomes will be more favourable. While the evidence for that is substantial it is not a proven cause 
and effect relationship. Our contention is also predicated on certain supportable assumptions 
regarding the mechanism of action. It is acknowledged that the effect of theophylline on 
inflammation chemistry is likely to be complex and to involve a range of inter-dependent cytokines, 
interferons, immune cells and other physiological systems that contribute to the control of innate 
immune responses, such as autonomic neuro-endocrine activity. It is not possible at present to posit 
a precise mechanism supported by linear biochemical logic in a molecule by molecule sequence. 
Indeed, it is probable, given the highly complex interactions of the innate immune system that the 
mechanistic order will vary between individuals and on different occasions depending on the type of 
stimulus, magnitude and rate of change of immune biochemical concentrations and the real-time 
status of associated physiological systems.  However, we argue that it is not necessary to resolve all 
components of the mechanism in order to predict an overall directional change or aggregate shift 
towards a less inflamed phenotype. We argue that our interpretation is sufficiently consistent with 
the observed effects of theophylline on key inflammatory cytokines and appears partially to explain 
the favourable clinical responses of patients with asthma, COPD and sepsis. Further insights into the 
various stages of the mechanism should emerge with further focussed empirical research in the 
future. Of course, MXs are not unique in this regard. Several other drugs are known to have immune 
modulatory properties that could be similarly useful, including statins, thalidomide, 4-
aminoquinolines and beta-adrenergic receptor blockers [56-60]. These all have subtle multi-point-of-
action effects on cytokine activity but are limited by lack of clinical evidence in COPD, or side effects. 
Some targeted monoclonal antibodies (MCAs) are highly effective in specific pathological contexts, 
for example anti-TNFα drugs for rheumatoid disease [61], but their role as broader spectrum 
immune dampers is less clear. Roflumilast, a selective phosphodiesterase-4 inhibitor suppresses 
airway inflammation in COPD [62] and thereby reduces the systemic inflammatory burden, but 
probably has little direct effect on the systemic inflammation. Other drugs with anti-inflammatory 
properties, such as salicylates, corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) 
largely act through cyclo-oxygenase [63] and phospholipase A2 [64] pathways that do not directly 
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involve cytokine mechanisms and, with the possible exception of some NSAIDs [65], do not appear 
to have an anti-sarcopenic effect. 
We also suggest that the predicted shortening of the post-infective, or post-exacerbation, 
inflammatory phase could lead to faster recovery from, or even avoidance of, important neuronal 
dysfunctions such as delirium, impaired balance, anorexia, low mood, lethargy and autonomic 
impairment, as well as reducing generalized oedema, myocyte dysfunction, sarcopenia, insulin 
resistance and other adverse metabolic states. It is reasonable to expect that such improvements in 
a patient’s physiological milieu would augment the benefits of the structured exercise components 
of pulmonary rehabilitation and contribute to improved functional outcomes. Thereby, the treated 
patient is expected to have a lower risk of becoming overtly cachectic, sarcopenic, frail and 
dependent.  In the case of infection, it is probable that the stabilizing effect on innate immune 
chemistry will be most effective if theophylline treatment is started towards the end of, or 
immediately after, antibiotic treatment so as to cause no blunting of the initial beneficial switch to a 
protective pro-inflammatory state as micro-organisms are destroyed, but before the detrimental 
prolonged tail of non-resolving inflammation is established. The ideal duration of treatment is not 
known but will probably be in the 3-6 weeks range, based on the observed duration of pro-
inflammatory augmentation after episodes of exacerbation or infection. However, further light can 
only be shed on these practical issues by empirical research. It is the opinion of the authors that until 
conclusive evidence from clinical trials is available the use of low-dose theophylline to suppress 
inflammation can be justified in COPD, particularly during recovery from exacerbations and during 
pulmonary rehabilitation. 
Conclusion 
Theophylline and other MXs at low doses might be useful to reduce the potentially deleterious 
inflammatory burden during and after exacerbations of COPD, and in other pro-inflammatory states. 
There is potential to reduce the progression of muscle weakness, to delay or avoid overt sarcopenia, 
and to reduce the incidence, duration and intensity of low mood, delirium and illness behaviour, 
particularly in aged patients and those with multiple co-morbidities. The anti-sarcopenic properties 
of MXs could also be exploited for benefit as adjunctive treatment during pulmonary rehabilitation. 
Properly designed clinical trials are now needed to establish whether or not these effects are of 
consistent clinical utility.  
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Legend for figure 1.  The immuno-modulatory effects of theophylline in sustained inflammation 
 
   
